C.R. Bard, Inc. (NYSE:BCR) Receives $264.90 Consensus Target Price from Analysts

Shares of C.R. Bard, Inc. (NYSE:BCR) have earned an average recommendation of “Hold” from the thirteen ratings firms that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, eight have given a hold recommendation, one has assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $273.80.

BCR has been the topic of several recent research reports. Zacks Investment Research raised C.R. Bard from a “hold” rating to a “buy” rating and set a $351.00 price target on the stock in a research note on Tuesday, June 13th. BMO Capital Markets cut C.R. Bard from an “outperform” rating to a “market perform” rating and set a $245.00 price target on the stock. in a research note on Tuesday, April 25th. Morgan Stanley cut C.R. Bard from an “overweight” rating to an “equal weight” rating in a research note on Monday, April 24th. BidaskClub cut C.R. Bard from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 19th. Finally, Jefferies Group LLC reaffirmed a “hold” rating on shares of C.R. Bard in a research note on Thursday, August 3rd.

In related news, insider John P. Groetelaars sold 23,687 shares of the stock in a transaction on Thursday, August 10th. The stock was sold at an average price of $318.73, for a total transaction of $7,549,757.51. Following the sale, the insider now directly owns 31,445 shares of the company’s stock, valued at $10,022,464.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.80% of the company’s stock.

Large investors have recently added to or reduced their stakes in the stock. UBS Asset Management Americas Inc. boosted its stake in C.R. Bard by 3.5% in the fourth quarter. UBS Asset Management Americas Inc. now owns 267,451 shares of the medical instruments supplier’s stock valued at $60,087,000 after buying an additional 9,134 shares during the period. Perigon Wealth Management LLC boosted its stake in C.R. Bard by 14.6% in the fourth quarter. Perigon Wealth Management LLC now owns 2,566 shares of the medical instruments supplier’s stock valued at $631,000 after buying an additional 327 shares during the period. Teachers Advisors LLC boosted its stake in C.R. Bard by 3.5% in the fourth quarter. Teachers Advisors LLC now owns 134,481 shares of the medical instruments supplier’s stock valued at $30,213,000 after buying an additional 4,500 shares during the period. Kentucky Retirement Systems acquired a new stake in C.R. Bard during the fourth quarter valued at approximately $1,199,000. Finally, Kentucky Retirement Systems Insurance Trust Fund acquired a new stake in C.R. Bard during the fourth quarter valued at approximately $535,000. 85.32% of the stock is currently owned by institutional investors.

Shares of C.R. Bard (BCR) traded up 0.19% during mid-day trading on Tuesday, hitting $319.75. 330,226 shares of the stock traded hands. C.R. Bard has a 52 week low of $203.63 and a 52 week high of $323.27. The stock has a market cap of $23.24 billion, a price-to-earnings ratio of 41.98 and a beta of 0.59. The firm’s 50-day moving average is $319.00 and its 200-day moving average is $283.44.

C.R. Bard (NYSE:BCR) last announced its earnings results on Thursday, July 27th. The medical instruments supplier reported $2.92 EPS for the quarter, beating analysts’ consensus estimates of $2.84 by $0.08. The company had revenue of $979.70 million during the quarter, compared to the consensus estimate of $976.53 million. C.R. Bard had a return on equity of 48.70% and a net margin of 14.99%. The firm’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.54 earnings per share. On average, analysts forecast that C.R. Bard will post $11.84 earnings per share for the current year.

The business also recently announced a quarterly dividend, which was paid on Friday, August 4th. Stockholders of record on Monday, July 24th were paid a $0.26 dividend. The ex-dividend date was Thursday, July 20th. This represents a $1.04 dividend on an annualized basis and a dividend yield of 0.33%. C.R. Bard’s dividend payout ratio is currently 13.67%.

TRADEMARK VIOLATION WARNING: “C.R. Bard, Inc. (NYSE:BCR) Receives $264.90 Consensus Target Price from Analysts” was first reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this story on another site, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The legal version of this story can be viewed at https://stocknewstimes.com/2017/08/12/c-r-bard-inc-nysebcr-given-average-rating-of-hold-by-brokerages-updated-updated.html.

About C.R. Bard

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Analyst Recommendations for C.R. Bard (NYSE:BCR)

Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply